Transcranial magnetic stimulation in animal models of neurodegeneration

Mohammad Uzair1, Turki Abualait2, Muhammad Arshad3, Woo-Kyong Yoo3,4, Ali Mir5, Reem Fahd Bunyan5, Shahid Bashir5,*

Abstract

Brain stimulation techniques offer powerful means of modulating the physiology of specific neural structures. In recent years, non-invasive brain stimulation techniques, such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation, have emerged as therapeutic tools for neurology and neuroscience. However, the possible repercussions of these techniques remain unclear, and there are few reports on the incisive recovery mechanisms through brain stimulation. Although several studies have recommended the use of non-invasive brain stimulation in clinical neuroscience, with a special emphasis on TMS, the suggested mechanisms of action have not been confirmed directly at the neural level. Insights into the neural mechanisms of non-invasive brain stimulation would unveil the safety and efficacy of this progressive approach. Therefore, animal studies investigating the mechanisms of TMS-induced recovery at the neural level are crucial for the elaboration of non-invasive brain stimulation. Translational research done using animal models has several advantages and is able to investigate knowledge gaps by directly targeting neuronal levels. In this review, we have discussed the role of TMS in different animal models, the impact of animal studies on various disease states, and the findings regarding brain function of animal models after TMS in pharmacology research.

Key Words: Alzheimer’s disease; depression; glial cells; neurorehabilitation; Parkinson’s disease; repetitive transcranial magnetic stimulation; transcranial direct current stimulation; transcranial magnetic stimulation

Introduction

Over the last two decades, understanding human cognition by non-invasive brain stimulation (NIBS) has received much attention and has advanced considerably. Hitzig (1838–1907), Fritsch (1838–1927), Ferrier (1843–1928), Sherrington (1856–1952), and Penfield (1976–1991) have significantly contributed to research on the electrical stimulation of the cortex to discover the organization and physiology of the human brain. In 1959, Kolin et al. stimulated the nerves of frogs through alternating magnetic fields for the very first time. Later in 1965, Bickford applied magnetic fields to stimulate the human peripheral nerve. This work was not pursued further because the long-lasting activation interval made it impossible to record the action potential of the nerve or muscles (Bickford and Fremming, 1965). Magnetic stimulation of frog nerves was also reported by Öberg (1973). However, in the following years, the technique was investigated only sporadically. In 1980, Merton and Morton (1980) electrically stimulated the motor cortex through the scalp using transcranial electrical stimulation (TES). In 1982, Polson et al. reported the first successful magnetic stimulation of the peripheral nerve. They applied 2-ms-duration pulses over median nerve magnetic stimulation and recorded the motor-evoked potentials (MEPs). TES became very useful for many purposes, but it was very painful. Later, in 1985, Barker et al. introduced transcranial magnetic stimulation (TMS) to stimulate the brain with no pain.

In this review, we provide an overview of NIBS while focusing mainly on TMS as an efficient method for studying cortical functions in different animal models. We also discuss the contribution of animal TMS studies validated for the treatment of human diseases and understanding the basics of neurophysiology and neurotransmission.

Database Search Strategy

The Cochrane Library, PubMed, EMBASE and Web of Science were searched to retrieve papers published up to 2020. Literature retrieval was performed using all possible ways including the reference lists and authors’ files from the included studies, in the protocol. A wide range of terms and related truncations including brain stimulation (BS), non-invasive brain stimulation (NIBS), transcranial magnetic stimulation (TMS), repetitive transcranial magnetic stimulation (rTMS), paired-pulse TMS, neurodegenerative diseases, neurodegenerative disorders, Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), depression, major depression, major depressive disorder, animals, animal models, mice, rats, monkeys, cognitive decline, cognitive function, neurocognitive, apoptosis,
neurotransmitters, neurotrophic factors, BDNF, NMDA, NMDAR, GABA, glutamate, oligodendrocytes, astrocytes, microglia, and neural stem cells were used. Combinations of Medical Subject Headings (MeSH) and text words were used. The same search terms were also used in other electronic databases.

What Is Transcranial Magnetic Stimulation?

TMS is a non-invasive tool for brain stimulation that electrically stimulates neural tissues, including the cerebral cortex, spinal nerves, cranial and peripheral nerves. TMS can potentially depolarize neurons and effectively evoke measurable effects. It does not require surgery, anesthesia, injections, or intravenous systems, and it causes little or no pain. TMS is performed based on Faraday’s principle of electromagnetic induction, established in 1838. When a high-voltage current passes through a coil, a varying magnetic field is generated. Near the scalp, this time-changing magnetic field induces currents opposite in direction to the original current in the coil. When the magnetic coil is positioned near the skull and a sufficiently strong stimulus is administered, the underlying brain tissue is stimulated (Cuypers and Marsman, 2020). TMS can be applied as single pulses of stimulation, or pairs of stimuli separated by variable intervals, or trains of repetitive stimuli at various frequencies to the same or different brain regions. Single-pulse TMS (sTMS) can be used to analyze central motor conduction time and motor cortical outputs, while paired-pulse TMS (ppTMS) can efficiently measure intracortical facilitation, inhibition, and impart significant effects on neuroplasticity (Cui et al., 2020). Trains of stimuli (repetitive TMS, rTMS) can regulate cerebral cortex excitability at the stimulated site and in remote areas, along with functional anatomical landmarks. rTMS has diverse effects on cognitive tasks, behavioral functions, and brain activity that depend on the stimuli frequency.

In recent times, TMS has widely become the well-established technique for the examination and modulation of the excitability of human brain areas, yet the basic cellular processes and mechanism behind this method are still unknown. Despite these anomalies, the prospective applications of TMS are enormous, particularly in the determination of the pathophysiology of the brain due to neurological and psychological disorders, and can be further developed and employed into clinically useful diagnostic and prognostic procedures, as well as in the therapeutic measures of various diseases. This tremendous potential of TMS has already been reported by numerous researchers, and requires many clinical trials on model animals to elaborate on the underlying mechanisms and yield options for novel therapeutic approaches.

Paired-pulse TMS

In this method, ppTMS utilizes two successive pulse stimuli via the same coil, with a short inter-stimulus interval (ISI) for a few milliseconds and a long ISI for tens to hundreds of milliseconds (Klomjai et al., 2015). Both of these pulses are delivered to the same regions of the dominant hemisphere to determine the inter-hemispheric inhibition or transcallosal inhibition (Cosentino et al., 2018). ppTMS methods are used to examine the inhibitory or excitatory intracortical networks that are stimulated by the intensity and ISI used (Mассé-Alarie et al., 2016; de Goede et al., 2020; Neige et al., 2020). The intensity of the first pulse, or conditioning stimulus, is applied at the sub-motor threshold. The intensity of the second pulse, also called the test stimulus, is applied at the supra-motor threshold (Premoli et al., 2018). The test stimulus induces MEPs, which are thought to be an outcome of a conditioning pulse. Thus, cortical excitability can be evaluated by use of a second stimulus (Kallioniemi et al., 2018).

Repetitive TMS

rTMS offers a safe and non-invasive technique that modulates cortical excitability, function, and inhibition. Moreover, rTMS causes neuronal polarization in the brain and has the potential to treat neurological and psychiatric disorders. The modulation of cortical excitability and disturbance in cortical network function depends on the stimulation parameters (Hanlon et al., 2018; Beynel et al., 2019; Singh et al., 2020). rTMS induces trains of electric currents to the brain at a depth of 2 cm, which are delivered through the pulsating magnetic fields. rTMS produces intermittent magnetic fields in the range of 1.5 to 2 Hz (Kloppenburg et al., 2015; Singh et al., 2020). The induced currents modulate neuronal excitability with frequencies ≥ 5 Hz (i.e. high-frequency rTMS (HF-rTMS)) or ≤ 1 Hz (i.e. low-frequency rTMS (LF-rTMS)). In contrast to sTMS, rTMS can regulate cortical activity following the stimulation frequency (Lage et al., 2016; Hanlon et al., 2018). High-frequency rTMS appears to increase cortical excitability, MEP size, and intercellular interactions (ICl), whereas low-frequency rTMS significantly decreases cortical excitability and enhances post-stroke motor recovery (Lage et al., 2016; Du et al., 2019). The recent literature shows that rTMS exerts long-lasting effects on cortical functions, as compared to non-repetitive MS (Chervyakov et al., 2015; Caglayan et al., 2019). These studies have revealed that increases in cell proliferation, regional cerebral blood flow, and synaptic plasticity are observed in neuronal circuits after high-frequency rTMS therapy. High-frequency rTMS also activates various cell signaling pathways, including brain-derived neurotrophic factor (BDNF), cyclic adenosine monophosphate-responsive element binding protein (CREB), and phosphatidylinositol 3-kinase/protein kinase B (Akt), to inhibit apoptotic cell death and promote neurogenesis following ischemia (Baek et al., 2018; Caglayan et al., 2019). Additionally, rTMS provides a non-invasive and effective neuromodulation approach for stimulating neurons and treating various neurological disorders.

The Molecular Mechanism Behind the Therapeutic Effects of Transcranial Magnetic Stimulation

TMS is an approachable and promising neuromodulation technique due to its ability to promote functional recovery of cortical function following a stroke (Agarwal et al., 2019; Caglayan et al., 2019). TMS promotes the recovery of the axonal terminals, structural integrity, cortical function, neuromodulation, affects gene expression and neurotransmitters, and produces neuronal recovery after a stroke by the action of the alternating magnetic field. TMS affects the stimulated cortical regions and other connected regions (Chervyakov et al., 2015; Baek et al., 2018; Aberra et al., 2020). However, although numerous studies have investigated the beneficial effects of TMS on brain stimulation, the precise mechanism behind the contribution of TMS remains incompletely understood.

TMS inhibits apoptotic cell death, prevents neuronal death, and promotes neuronal survival

In neurodegenerative conditions, including stroke, trauma, severe epileptic seizures, Alzheimer’s disease (AD), and motor system disorders, there is an increase in neuronal cell death. It is believed that apoptosis acts as a major cell death pathway in neurons (Chi et al., 2018; Pemberton et al., 2021), particularly neurons in the ischemic region. TMS prevents neuronal death by inhibiting several members of the B-cell lymphoma 2 (Bcl-2) family, particularly those that stimulate apoptosis, i.e., Bad, Bax, and Bcl-xS (Kale et al., 2018; Pemberton et al., 2021). Numerous studies using animal models of transient ischemia and prolonged ischemia found that TMS protects neurons and inhibits programmed cell death following an ischemic event.
TMS treatment recovers neuronal functioning after cerebral ischemia/reperfusion injuries, as observed in rat models (Feng et al., 2005; Guo et al., 2014, 2017). Gao et al. (2010) studied the neuroprotective effects of HF-rTMS in a transient ischemic mouse model to investigate the mechanism underlying these effects. They found that glucose metabolism was significantly higher, and caspase-3 positive cells were reduced following rTMS treatment. rTMS activates Bcl-2 cells and decreases Bax, indicating that rTMS inhibits apoptotic pathways in the ischemic brain area, infarct volume, and lesion size by seizing apoptosis (Namura et al., 1998; Figure 1). Ke et al. (2010) studied the impact of LF-rTMS on neuronal protein expression in the hippocampus of a mouse model of epilepsy. They concluded that low-frequency (0.5 Hz) rTMS exerted anti-apoptotic and anti-epileptic effects, as it upregulated Bcl-2 expression and Fas protein expression decreased. Protein levels of Bax-induced neuronal cell death, cleaved caspase-1, and cleaved caspase-3/caspase-3 decrease after LF-rTMS treatment (Guo et al., 2017; Luo et al., 2017; Baek et al., 2018; Caglayan et al., 2019). Prolonged exposure to rTMS significantly increases BDNF mRNA levels following ischemia, which may contribute to synaptic plasticity (Müller et al., 2000; Ogiue-Ikeda et al., 2005). Additionally, rTMS significantly activates Bcl-2, decreases Bax, and the number of TUNEL-positive cells in the ischemic hippocampus (Guo et al., 2017). Hence, many studies suggest that TMS exerts its beneficial effects by blocking apoptosis, mainly by regulating the expressions of BDNF, Bcl-2, and Bax (Table 1).

### Table 1: Transcranial magnetic stimulation (TMS) parameters and its beneficial therapeutic effects on the brain

| Authors | Animal model/sample | TMS parameters | Effects | Results and conclusions |
|---------|---------------------|----------------|---------|-------------------------|
| Fujiki et al., 2003 | Mongolian gerbil models of transient ischemia | Neuronal cell death induced by transient ischemic attack | 5-, 10-, 25-, and 50-Hz rTMS, with duration of one train 8 s | 25-Hz TMS induced ischemic tolerance against delayed neuronal death while neuronal density was substantially higher in the CA1 region |
| Gao et al., 2010 | Rat models of MCAO | Positron emission tomography neuroimaging for evaluation of cerebral glucose metabolism; immunohistochemical staining for evaluation of neuronal activity | 20-Hz rTMS for 5 s, repeated 10 times | Increased neurological scores, decreased cortical and striatal infarct volumes, decreased caspase-3 expression, and increased Bcl-2/Bax ratio |
| Yoon et al., 2011 | Rat models of MCAO | Apoptotic markers | Stimulation with 10 Hz frequency (a total of 3500 pulses) | Increased Bcl-2 and decreased Bax expression |
| Ke et al., 2010 | Rat models of lithium-pilocarpine-induced epilepsy | Apoptotic markers | 0.5 Hz, 75% threshold intensity, 20 times for 5 d | Increased Bcl-2 protein expression and decreased Fas protein expression |
| Baek et al., 2018 | Mouse neuro-2a (N2a) cell culture | The differential effects of repetitive magnetic stimulation depending on frequency on neuronal model of ischemia/reperfusion injury | 0.5 Hz TMS, on-off interval of 3 s | Increased cell proliferation, activated ERK and AKT pathway, inhibited apoptosis, and increased BDNF expression |
| Caglayan et al., 2019 | Mouse models of focal cerebral ischemia | Influence on injury development, cerebral blood flow, apoptotic markers | 5 s stimulation followed by 55 s rest for a total duration of 10 min at either 1 or 20 Hz | Decreased infarct volume, enhanced microcirculation, prevented apoptosis, and reduced inflammatory responses |
| Guo et al., 2017 | Rat models of MCAO | rTMS against stroke cognitive impairment | 10 Hz stimulation followed by rest for 50 s, repeated 10 times (300 pulses per day) | Promoted the proliferation of neural stem cells; increased BDNF TrkB and Bcl-2 protein expression, and increased Bax expression |
| Luo et al., 2017 | Ischemic rats | BDNF/TrkB pathway | 20 Hz rTMS | Increased the number of K67/DCX, K67/Nestin, and K67/NeuN-positive cells, elevated protein level of BDNF and TrkB |
| Müller et al., 2000 | Rats | Neurotrophic factors and neuropeptides, BDNF mRNA expression | 3 trains at 20 Hz frequency for 2.5 s, 150 stimuli/d | Upregulated the BDNF and CCK mRNA expression |
| Ogiue-Ikeda et al., 2005 | Rat models of ischemia | Ischemic tolerance | 0.75 T rTMS, 1000 pulses/day for 7 d | Increased hippocampal viability |

BDNF: Brain-derived neurotrophic factor; MCAO: middle cerebral artery occlusion.
TMS regulates the levels of neurotransmitters and neurotrophic factors and exerts neuroprotective effects. Notably, recent research has shown that rTMS upregulates endogenous neurotrophic content, i.e., brain-derived neurotrophic factor (BDNF) in the brain (Guo et al., 2017; Levy et al., 2018). Furthermore, BDNF is associated with post-stroke rehabilitation and neuronal protection. Similarly, several studies have shown that the increased expression of BDNF in tissues surrounding the infarction zone during the first week following a stroke is involved in neural protection during acute ischemic damage and neurogenesis (Houlton et al., 2019; Liu et al., 2020; Roslavtceva et al., 2017; Levy et al., 2018). Moreover, low-frequency (1 Hz) rTMS effectively increases hippocampal neurotrophins (NGF and BDNF) and NMDA receptor levels (Tan et al., 2013b).

### Table 2

| Author                  | Animal model/sample | Outcome measures                  | TMS parameters | Effects                                                                 | Results and conclusions                                                                 |
|-------------------------|---------------------|-----------------------------------|----------------|-------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| Yang et al., 2010       | Rat models of Parkinsonian | Dopamine level                    | 0.5 Hz and 500 pulses | Decreased cyclooxygenase-2 and tumor necrosis factor-α levels, and promoted dopamine release in the striatum | rTMS promotes functional and behavioral recovery, exhibits antioxidant and anti-inflammatory effects and treats Parkinson’s disease |
| Kanno et al., 2004      | Rat models of Parkinson’s disease | Extracellular dopamine concentrations | 500 stimuli from 20 trains per day, at 25 Hz for 1 s with 1-min intervals between trains | 60% TMS increased the dopamine production in the dorsolateral striatum and prefrontal cortex | 60% TMS promotes functional and behavioral recovery, exhibits antioxidant and anti-inflammatory effect and treats Parkinson’s disease |
| Ba et al., 2017         | Rat models of lactacystin-induced Parkinson’s disease | Ubiquitin proteasome system impairment | Stimulation at 0.5 Hz frequency, daily for 4 wk, each train consisted of 500 pulses | Increased the number of tyrosine hydroxylase-positive dopaminergic neurones, striatal dopamine levels, decreased the expression of cleaved caspase-3, COX-2 and tumor necrosis factor-α | TMS exhibits anti-apoptotic and anti-inflammatory effects, improves motor disability, and treats Parkinson’s disease |
| Ko et al., 2008         | Healthy volunteers  | PET findings, cognitive task, DLPFC stimulation | cTBS at 50 Hz repeated at 200-ms intervals (i.e. 5 Hz) | Increased dopamine synthesis and release. TMS exhibited effects limited only to the left DLPFC stimulation while right DLPFC stimulation did not influence task performance | TMS affects task performance, synaptic plasticity, and modulates cognitive task |
| Wang et al., 2011       | Rats                | BDNF and TrkB levels              | 5-Hz rTMS for 5 d    | Increased serum BDNF level, activated BDNF-TrkB-NMDAR signaling pathway, increased recruitment of PLC-γ1 and shc/N-shc to TrkB | TMS increases cortical synaptic plasticity, promotes cortex functioning and maturation of the immune system |
| Tan et al., 2013b       | Rat models of Alzheimer’s disease | Level of neurotrophins in the hippocampus | 20 Burst trains, each train contained 20 pulses at 1 Hz, in total 400 stimuli | Improved spatial memory, Aβ1–42-mediated memory deficits, partially rescued Aβ1–42-mediated hippocampal LTP impairment, and increased NMDA-receptor expression | TMS rescues hippocampal LTP impairment and spatial memory upregulates neurotrophin factors, and treats Alzheimer’s disease |
| Zhang et al., 2015      | VaD rat model       | Spatial learning and memory abilities, BDNF, VEGF, and NMDAR expression | 200 Magnetic stimulation pulses of 5 Hz rTMS daily | Enhanced LTP, increased BDNF, VEGF, and NMDAR expression | TMS improves spatial learning and memory abilities |
| Baruth et al., 2010     | Autism spectrum disorder patients | EEG, gamma bands                 | 1 Hz rTMS treatments for 12 wk | Improved gamma activity and cortical inhibitory tone | TMS improves cortical activity, response accuracy, and treats autism spectrum disorder |
| Trippe et al., 2009     | Anesthetized or sedative mice | Expression of GAD65, GAD67, and GAT-1 | Intermittent and continuous theta burst (iTBS, cTBS), and 1-Hz stimulation | Reduced expression of GAD67, and increased expression of GAD65 and GAT-1 | TMS increases cortical excitability, neurotransmission, neural excitability, and synaptic plasticity |
| Grohn et al., 2019      | Healthy volunteers  | Pilot MRI/MRS study               | 1-Hz TMS           | Increased GABA concentration in stimulated motor cortex, slightly increased total creatine, and decreased aspartate and glutamate | TMS exhibits neuromodulatory and neurotransmitter effects and improves cortical function |
| Pascual-Leone et al., 1994 | Healthy volunteers | Human motor cortex and excitation | 1, 3, 5, 10, 20, and 25 Hz rTMS | Increased amplitude of MEPs and lasting excitability changes | TMS increases neural excitability |
| Chen et al., 1997a      | Healthy volunteers  | Motor cortex excitability         | 0.9 Hz for 15 min   | Decreased cortex excitability                                           | TMS exhibits neuroprotective effects |

BDNF: Brain-derived neurotrophic factor; cTBS: continuous theta burst stimulation; DLPFC: dorsolateral prefrontal cortex; EEG: electroencephalography; GABA: gamma-aminobutyric acid; iTBS: intermittent theta-burst stimulation; LTP: long-term potentiation; MRI: magnetic resonance imaging; MRS: magnetic resonance spectroscopy; NMDA: N-methyl-D-aspartate; NMDAR: N-methyl-D-aspartate receptor; PET: positron emission tomography; rTMS: repetitive transcranial magnetic stimulation; VEGF: vascular endothelial growth factor.
Vascular endothelial growth factors A and B (VEGF-A and VEGF-B) are angiogenesis-related genes with neurotrophic and neuroprotective effects. Studies have found that high-frequency rTMS upregulates VEGF gene-expression, which in turn enhances neurogenesis (Sun et al., 2006; Zhang et al., 2015; Caglayan et al., 2019; Fukuda et al., 2020). Following a stroke, glutaminergic excitotoxicity induces cell death and prevents GABAergic inhibition. Ischemia activates the release of glutamate from neurons, as well as glial cells, inducing acute insult to nerve cells that leads to cell death (Belov Kirdjova et al., 2020). Glutamate is a crucial amino acid in the central nervous system (CNS) that regulates ischemia-induced excitotoxicity (Pinky et al., 2018). Glutamate excitotoxicity may be established after traumatic injury and neurodegenerative disorders, including AD (Belov Kirdjova et al., 2020), PD (Albaugh et al., 2020), and Huntington’s disease (HD) (Crabbé et al., 2019). Glutamnergic excitotoxicity and GABAergic inhibition interaction may affect neuroregenerative processes (Agarwal et al., 2019). Various studies have demonstrated that post-rTMS treatment-induced increases in the level of gamma-aminobutyric acid (GABA) in the medial prefrontal cortex (Trippre et al., 2009; Baruth et al., 2010) and the ipsilateral cortex, accompanied by a decrease in the level of GABA in the contralateral cortex (Gröhn et al., 2019). GABA can stimulate neurite outgrowth, extend the neural network, enhance synaptogenesis, promote neuronal regeneration and differentiation, and increase gene expression (Wu and Sun, 2015; Niklson-Chirou et al., 2020). These investigations open a new pathway to understanding the molecular mechanism behind the neurogenesis strategies of TMS by studying neurotrophic factors (such as BDNF and DA) and neurotransmitters (such as GABA and glutamate).

TMS modulates non-neuronal cells (oligodendrocytes, astrocytes, microglia, and adult neural stem cells) and exerts therapeutic effects

TMS therapy is an effective way of diagnosing and treating neurodegenerative diseases, stroke, and ischemia. The insight mechanism of the neuroprotective effect of TMS is still not elucidated clearly. Many pieces of research focused on the beneficial effects of TMS on non-neuronal cells, also known as glia (Yang et al., 2018; Cullen et al., 2019). Gial cells constitute the majority of cells in the adult brain, many folds higher than neurons (Jäkel and Dimou, 2017). Neuroglial cells are represented by oligodendrocytes, astrocytes, microglia, and adult neural stem cells (NSCs). These non-neuronal cells do not conduct an electric impulse but play an important role in maintaining tissue homeostasis and providing protection and support to neurons, immune surveillance, and neurotransmission. Central nervous system (CNS) dysfunction or stroke leads to the death of not only neurons but also neuroglia (Jäkel and Dimou, 2017). There are few studies on how TMS regulates glial cell activity; however, a small number of studies were done in animal models (Table 3). Neuroglial cells exhibit an important role behind the mechanism of TMS in brain recovery, which has not been greatly explored.

Effects of TMS on oligodendrocytes

Oligodendrocytes are the highly specialized myelinating neuroglial cells of the central nervous system (CNS). Oligodendrocytes, formed by the proliferation of oligodendrocytes progenitor cells (OPCs), support axons through myelin production, insulation, and optimize action potential conduction (Pepper et al., 2018; Valério-Gomes et al., 2018). They are the susceptible target of injury in a number of neurological disorders and ischemia. As similar to neurons, oligodendrocytes are highly susceptible to damage by oxidative stress, apoptotic pathways, and trophic factors lack (Cappriano et al., 2012; Szebeni et al., 2014). rTMS treatment regulates the neural modulation by modulating GABAergic neurons (Dubin et al., 2016), BDNF (Luo et al., 2017), and VEGF (Zhang et al., 2015). These factors regulate the maturation of oligodendrocytes. Thus, TMS could potentially enhance oligodendrogenesis and myelination (Cullen and Young, 2016). Cullen et al. (2019) examined the therapeutic effects of rTMS, delivered as an iTBS pattern, on the oligodendrocytes in a healthy CNS of mice. The results determine that rTMS enhances the number of new premyelinating oligodendrocytes, proliferation, and survival rate of oligodendrocytes. LF-rTMS also enhances myelination, and the increase in myelination cells observed in the cortex region of the adult mice brain (Cullen et al., 2019). Recently, Dolgov et al. (2020) report low-field magnetic stimulation (LFMS) increases the oligodendrocytes progenitor cells differentiation by activating transforming growth factor-beta (TGF-β). In LF-rTMS treated rat central glia-4 (CG4) cell line culture, the elevated level of TGF-β, as well as an increase in the number of cells possessing complex branches and oligodendrocyte progenitor cells observed (Dolgov et al., 2020). The proliferating oligodendrocyte progenitor cells were also found to maintain myelination and remyelination of white matter and ensheathment of axons after SCI. The electrical stimulation of motor cortical neurons results in the increase of oligodendrocyte development and myelin formation in the damaged spinal cord (Li and Li, 2017). Thus, the magnetic stimulation can potentially promote oligodendrocyte differentiation and proliferation, which in turn, play an important role in the treatment of CNS disorders and demyelination diseases.

Effects of TMS on astrocytes

Astrocytes are structural, metabolic, and supportive components of neuronal tissues that guide axons, support synapses and regulate the blood brain-barrier. Astrocytes also prevent neurons from oxidative stress, maintain homeostasis at a synapse, and control neuronal signaling (Seifert and Steinhauser, 2013; Allen and Eroglu, 2017). Astrocytic glial cells have an important role in neuroinflammation after neurodegenerative conditions, stroke, and ischemia (Cekanaviciute and Buckwalter, 2016). Recent researches show that the astrocytes are likely to be an important therapeutic target for neuroprotection, neuro-restoration, and proliferation following stroke and CNS disorders (Barreto et al., 2011; Liu and Chopp, 2016). The effects of astrocytes have been well-studied while studying the low- and high-frequency rTMS in mouse models. The rTMS treatment, 1 Hz and 20 Hz applied to the rat models of neuropathic pain significantly regulates the expression of astrocytes. The expression levels of neuronal nitric oxide synthase (nNOS), glial acidic fibrilary acidic proteins (GFAP), and the co-localization with 5-bromo-2-deoxyuridine (BrdU) in astrocytes down-regulated after 20 Hz rTMS treatment, as compared with 1 Hz group. These findings suggest that high-frequency (20 Hz) may alleviate neuropathic pain by decreasing the nNOS expression and significantly inhibits the activity and proliferation of astrocytes (Yang et al., 2018). In another study, high-frequency rTMS promotes metabolic and c-Fos activities in the cortex but does not affect astroglial reactivity and microglia reactivity in the hippocampus of healthy rats (Zorzo et al., 2019). rTMS also affects the polarization of astrocytes during cerebral ischemia. Hong et al. (2020) demonstrated that 10 Hz rTMS treatment inhibits neurotoxic astrocyte proliferation and decreases TNF-a, apoptosis, and infarct volume. The anti-inflammatory mediator IL-10 increases after rTMS, thus enhancing neural plasticity and functional recovery following cerebral ischemic stroke in the MCAO rat model subjected to oxygen-glucose deprivation/reoxygenation (Hong et al., 2020). The NIBS techniques have also been reported to exert therapeutic potential against depression, and astrocytes play an important role in this regard. rTMS exerts anti-depressive properties, which depend on different parameters. rTMS treatment has been shown inhibit the over-expression of sirtuin 1 (Sirt1)
TMS modulates non-neuronal cells (oligodendrocytes, astrocytes, microglia, and adult neural stem cell) and exerts therapeutic effects

**Results and conclusions**

**Drosophila**

**TMS parameters**

**Outcomes measures**

**Neural stem cells culture**

**Rat models of depression**

**Healthy rats**

**Excitatory neuronal**

**1 and 20 Hz TMS**

**Rats injected with 6 x 10**

**Primary astrocytes and**

**0.2 Hz TMS**

**Neural metabolism and**

**60 Hz TMS**

**Microglial and astrocyte reactivity. In addition, inflammatory**

**and MAO-A, in astrocytes, in the prefrontal cortex (PFC) and the cortex-derived astrocytes from the newborn rats (Peng et al., 2018). tDCS activates astrocytes by promoting the intracellular Ca+ signaling that supports synaptic plasticity and amelioration of depression-like behavior (Monai and Hirase, 2018). TMS treatment enhances astrocytosis and cell density and can treat neuro-inflammation (Medina-Fernández et al., 2017).**

**Effects of TMS on microglial cells**

Microglial cells are a specialized type of macrophages that remove damaged neurons, protect the injured brain, and mediate immune response in the CNS (Faustino et al., 2011; Zhao et al., 2017). In the absence of microglia, the level of cytokines and chemokines was observed to increase following ischemia, thus increasing infarct volume and profound brain injury (Faustino et al., 2011). Microglia could contribute as a diagnostic marker for neurodegenerative disorders (Hickman et al., 2015; Kwon and Koh, 2020). In addition, little is reported on the effects of TMS on microglial cells. However, a study by Zorzo et al. (2019) investigated the effects of 3 days of high-frequency rTMS by examining glial cells in mice. Zorzo et al. (2019) found that high-frequency rTMS did not induce microglial and astrocyte reactivity. In addition, inflammatory
Electrical stimulation has been shown to assist NSCs to develop into neurons, astrocytes, or glial cells (Zhao and Moore, 2018). NSCs are self-renewing and multipotent cells that have the potential to develop into neurons, astrocytes, oligodendrocytes, or glial cells (Zhao and Moore, 2018). Electrical stimulation has been shown to assist NSCs to migrate directionally and differentiate into required cells, which significantly facilitates the treatment of CNS disorders (Huang et al., 2015). Peng et al. (2019) transplanted differentially expressed human NSCs (hNSCs) in an MCAO rat model and treated them with rTMS. The findings show that transplantation of hNSCs followed by rTMS treatment can potentially increase BDNF level, neurogenesis, and functional recovery after ischemic stroke. In another study, Kremer et al. (2016) transplanted human dental pulp stem cells (DPSCs) in the rat cortex followed by rTMS. DPSC survival and migration were found to be decreased or inhibited. In addition, caspase-3 apoptosis pathway and glutamate expression increase in the implanted DPSCs due to rTMS, resulting in reduced survival of DPSCs (Kremer et al. 2016). Caspase-3 expression localized to the implanted DPSC site (Kremer et al., 2016). The rTMS therapy (10 Hz) enhances NSCs proliferation via regulation of micro RNA 25 (miR-25) expression and pathway after focal cerebral ischemia in the subventricular zone (SVZ) of the rat model (Guo et al., 2014). Similarly, it has been found that repetitive magnetic stimulation can potentially increase NSCs proliferation by upregulating miR-106-25 (Liu et al., 2015). Therefore, TMS combined with stem cell therapy exerts effective therapeutic effects and promotes brain recovery.

### TMS affects calcium ions (Ca\(^{2+}\)) currents/signalizing and promotes neural regeneration and neuroplasticity

The voltage-gated calcium ion (Ca\(^{2+}\)) channels play a key role in Ca\(^{2+}\) signaling in neuronal cells and are necessary for neurotransmitter release. Ca\(^{2+}\) channels regulate neuronal excitability, neurite length, gene expression, and protein levels. The voltage-gated Ca\(^{2+}\) channels and Ca\(^{2+}\) signaling also have fundamental roles in CNS disorders, such as ischemia, stroke and neuropathic pain (Benarroch, 2010). It also has been found that astrocytes and their receptors, including γ-aminobutyric acid (GABA), can mediate Ca\(^{2+}\) signaling (Mederos and Perea, 2019). After ischemia, Ca\(^{2+}\) signaling exerts harmful effects on neurons by enhancing neuronal injury (Ding, 2014; Chung et al., 2015). TMS has been reported to regulate Ca\(^{2+}\) signaling, thus promoting neuroplasticity and neuroregenerative effects (Table 4). A recent study reported that plasma calcium levels increased significantly both in vitro and in vivo in humans after rTMS sessions (Stateman et al., 2014). Luo et al. (2019) investigated the effects of rTMS on neuroplasticity, neurotransmission, and recovery after nervous dysfunction by using Drosophila whole brain model. Luo et al. (2019) also examined the changes in calcium currents after rTMS at different frequencies (1 Hz and 100 Hz). It has been observed that rTMS regulates calcium current density and activity in a time-dependent manner. The calcium current density was found to be inhibited in the acute group, activated in the 12-hour group, and no changes were observed in the 24-hours group (Luo et al., 2019). The high-frequency rTMS (20 Hz) significantly increases intracellular calcium concentrations in the cortical neurons and may lead to long-term plasticity (Banerjee et al., 2017). These results were also observed by Tan et al. (2013a) that 1 Hz rTMS significantly upregulated Ca\(^{2+}\) currents. Moreover, tDCS promotes intracellular Ca\(^{2+}\) signaling, supports synaptic plasticity, and ameliorates depression-like behavior (Monai and Hirase, 2018). However, after rTMS, Ca\(^{2+}\) current density decreased in Drosophilla (Luo et al., 2019). tDCS also promotes the intracellular Ca\(^{2+}\) signaling that promotes brain plasticity by forming neurons, astrocytes, and microglial cells. tDCS activates the astrocytic Ca\(^{2+}\) signaling and plays an important role in depression treatment (Monai and Hirase, 2018). Calcium signaling is essential for pre-synapses, synapses, neural circuit activity, long-term plasticity, and neural plasticity. The electrical stimulation plays an essential role in regulating voltage-gated calcium ion channels and calcium signaling.
Animal Models for Studying TMS

Despite the fact that rTMS has often been implemented in therapeutic clinical trials, its basic mechanisms have not been robustly considered in animal models (Wagner et al., 2007a). Some animal models were used to investigate the mechanism underlying the effects of TMS, but the spatial and temporal dynamics of stimulation patterns remain poorly understood (Boonzaier et al., 2018). As TMS becomes a universally established therapeutic choice, more animal models are needed to examine its long-term safety and adequacy. An ideal animal model would target the behavioral correlates of stimulation in conscious and freely moving subjects.

Animal models for TMS will be helpful for studying the interactions between stimulation-induced changes in neuronal activity, plasticity, and changes in behavioral phenotypes. Most research has focused on the comparative consideration of normal and affected brain functions and the intensification of brain mapping. Animal models could play a potential role in the development of new therapeutic interventions, however, stimulation factors remain yet to be investigated. Although TMS studies involving animal models have distinctive limitations, prospective studies would lead to the provision of more precise data and cannot be discounted.

In 1990, rats were used to study TMS for the first time, after which there was a boom in animal TMS studies. Such studies include animal models of stroke, ischemia (Guo et al., 2017; Boonzaier et al., 2018), vascular dementia (Zhang et al., 2018), Alzheimer’s disease (Bagattini et al., 2020), Parkinson’s disease (Ba et al., 2017), and Huntington’s disease (Eddy et al., 2017). Animal models of neurodegenerative disease should fully model the human characteristics of the disease. Although rodents (mice, rats) are considered the most promising animal models for studying the function and behavior of the brain, they are not the only choice for TMS research. One major disadvantage is the ratio of head size to coil size in rodents (Koponen et al., 2020). TMS can stimulate human brains, and the large surface area of the human brain allows currently available coils to differentiate the various areas in the human brain. However, the smallest coils currently available can stimulate the entire rodent brain (Boonzaier et al., 2020). Moreover, the low effectiveness of magnetic stimulation in a rodent brain is another critical drawback, which could make the usefulness of rodent studies debatable (Boonzaier et al., 2020). Although smaller coils have been recently developed to cope with this issue, rodent studies of TMS remain limited in their applicability to the action of TMS in humans. These smaller coils tend to overheat, limiting the number of high-frequency train pulses and reducing field power (Funke, 2017). Nonhuman primates also seem to be promising as the large surface area of their brains minimizes focality issues, and they can be trained in many human-like behaviors.

However, animal experimentation also tends to have the following barriers: (1) the cost of maintaining and housing the animals is prohibitive; (2) it can be difficult to train animals to calmly tolerate the loud noises associated with rTMS; and (3) from a technical standpoint, rTMS causes continuous twitching of their jaw muscles (Wagner et al., 2007b; Potashkin et al., 2011). However, cats may represent a good intermediate between rodents and primates for focal stimulation due to their moderate brain size, i.e., moderate coil ratio, and their amenability to training for experimentation (Wagner et al., 2007a).

Significance of animal models for studying TMS

Various animal studies have been used to investigate the basic molecular mechanism behind TMS effects. As previously mentioned, most of these studies have been performed using rodents, and it is still challenging to transfer findings from these studies to humans. The application of TMS in humans is considerably focal, as the brain surface area in humans is sufficiently large for currently manufactured coils to differentiate the various areas of the human brain. However, TMS cannot be administered focally in rodents due to the small size of their brains as compared to the sizes of currently available coils, and thus the entire brain receives magnetic stimulation (Weissman et al., 1992; Belmaker and Grisaru, 1998). According to Weissman et al. (1992), the efficiency of magnetic stimulation is reduced in a small rodent brain, and hence, the sustainability and efficacy of studies using rodents are still uncertain. Stimulation patterns have not been examined for their correspondence to comparative patterns used under clinical conditions (Weissman et al., 1992). When a figure-eight-shaped coil is applied tangentially to the volume conductor, electrical activity significantly increases focally, and a sharp central peak parallel to the long axis is bounded on each side by smaller peaks (Maccabee et al., 1990). The sound of a magnetic stimulator and the effects of TMS on muscles result in a stressful experience for rats. Therefore, there is a need for a sham-controlled group. Extracellular dopamine levels are considerably increased because of stress in the prefrontal cortex (PFC) of the rat brain (Kanno et al., 2004; Cho and Strafella, 2009), the environmental exposure, and the handling process (Schwarz et al., 2000). The intensity of stimulus greatly influences extracellular DA levels in the PFC (Feenstra and Botterblom, 1996; Volkow et al., 2019).

Transcranial Magnetic Stimulation Applications in Animal Models

Combining animal models of experimental neurological disorders with TMS treatment allows the study and evaluation of the possible mechanism behind the therapeutic properties of TMS, the diagnostics used, and their application in human patients. This information should clarify the feasible utilization of this non-invasive procedure in the treatment of neurodegenerative disorders.

Neurodegenerative disorder models

There are numerous difficulties during generalization of the results from animal models to humans. The factors that must be considered include the animal models used, the...
type, degree of severity, duration of the disease and the
damage induced, the interval of surgical procedures, the
size and location of lesions, the ages and sexes of animals,
handling procedures such as feeding, maintenance, and the
potential effects of pharmacological stress agents. Despite
this, animal damage and repair models have been the reason
for renowned discoveries in neurological sciences and
neurorehabilitation that were not possible through human
studies.

**Huntington’s disease model**
The utilization of electromagnetic forces in neurobiology
is usually restricted to investigation of neurodegenerative
conditions. However, electromagnetism has been recently
applied in neurology as the therapeutic intervention has
received more attention, and new techniques and devices
have been developed. HD is an autosomal dominant
progressive neurodegenerative disorder that occurs because
of the dramatic degeneration of the basal ganglia, particularly
of GABAergic neurons in the striate nucleus, stimulating
particular cognitive, behavioral, and motor degeneration
(Naarding et al., 2001). The molecular mechanism of HD is
still unknown, and thus no efficient treatment is currently
available. However, electrophysiology studies have shown
that abnormal MEPs might be associated with altered excitability
of the cortico-spinal system as a result of basal ganglia
dysfunction (Meyer et al., 1992), while examination using TMS
has revealed a decline in cortical excitability before the onset
of clinical symptoms. These findings suggest that TMS and
other electrophysiological changes might serve as markers
of disease progression (Lorenzano et al., 2006; Schlipping
et al., 2009; Hartmann et al., 2016). Crupi et al. (2008) observed
impairment of both cortical and brainstem LTP-like plasticity
in symptomatic HD patients, which is similar to the LTP deficits
reported in animal models of HD. The studies have shown that
continuous TMS (at 60 Hz and 0.7 mT) in a 3-nitropropionic
acid (3NP)-induced HD-like rat model prevented the
physiopathological changes caused by 3-NP and also reversed
these changes following damage (Tüneez et al., 2006; Medina
and Tüneez, 2010), while enhancing animal behavior and
decreasing apoptosis and oxidative-damage markers. The
current study also supported the findings of Brusa et al. (2005)
who reported that low-frequency (1 Hz) TMS treatment
promoted choreiform movements in HD patients. Likewise,
Ihara et al. (2005) examined a decrease in oxidative-damage
markers following rTMS in the cerebrospinal fluid of patients
with spinocerebellar degeneration. Taken together, these data
suggest a possible therapeutic role for TMS. Further research
is required in which animal models will be crucial.

**Alzheimer’s disease model**
AD is a progressive neurodegenerative condition of the
central nervous system characterized by irreversible memory
loss and cognitive impairment. Even though extensively
examined, the mechanism underlying its physiopathology
and pathogenesis remains elusive. Notably, basic and clinical
studies have demonstrated that altered neuropsychiatry, the
neurotransmitter system, and synaptic failure are putative
common denominators involved in the pathogenesis
mechanism. Indeed, synaptic dysfunction is noted in the
early stage of AD and has become a therapeutic target for
pharmacological agents. Mouse models of AD have typically
focused on hippocampal long-term potentiation (LTP)
impairment as a molecular mechanism associated with
synaptic plasticity (Mango et al., 2019). Battaglia et al. (2007)
noted that neocortical plasticity impairment was correlated
with functional deficits of NMDA glutamate receptors in both
AD patients and APP/PS1 transgenic mice.

Cappa et al. (2002) reported the activation of the dorsolateral
prefrontal cortex following rTMS during verb processing and
auditory word recognition, while Cotelli et al. (2006) found
that rTMS treatment of the DLPFC accelerated action naming
in the control group and enhanced naming performance in
AD patients. However, the exact mechanisms involved
with improved naming and speech following rTMS are still
largely unknown. Cotelli et al. (2008) also demonstrated that
rTMS application over the DLPFC improved action naming
even in the advanced stages of AD, and proposed that rTMS
may enable the brain to recover damaged function during
disease development. It has recently been reported that high-
frequency rTMS (20 Hz) of the DLPFC improves language
performance and object naming in patients with AD (Cotelli
et al., 2010). These studies suggest both the beneficial and
therapeutic effects of rTMS and its potential usefulness for
behavioral and cognitive rehabilitation. However, it should
be noted that the induction of long-term changes in cortical
excitability depends upon a number of factors, including
stimulation intensity and frequency, site of stimulation, and
the number of runs. Further research and accurate analysis of
these elements are required in order to assess the potential
for extrapolating clinical findings in animal models to humans.

**Future studies**
Future studies on mouse models would be crucial in
understanding the mechanisms and effects of TMS on the
brain. Although investigators have remained unable to
influence specific behaviors, stimulation of the entire
brain has facilitated the study of structures that are too
too deep to stimulate safely in humans. The effects of neuronal
excitability and the learning process in memory tasks have
been well elaborated using low- and high-frequency rTMS
on the hippocampus (Lage et al., 2016). Low-frequency (1
and 8 Hz) rTMS temporarily impaired performance on object
recognition tasks, while high-frequency (15 Hz) stimulation
improved memory in the test animals (Ahmed and Wieraszko,
2006). Moreover, the correlation of these findings with neural
mechanisms has been investigated, and it was determined
that hippocampal slices from subjects exposed to 15 Hz
rTMS showed increased synaptic efficiency and LTP (Ahmed
and Wieraszko, 2006). The LTP induced by rTMS caused
numerous similar neuronal changes, while high-frequency
rTMS triggered neural activation, upregulated gene expression
(Fujiki and Steward, 1997), and varied or altered monoamine
regulation (Keck et al., 2002).

Furthermore, mouse research on rTMS and plasticity has
also assisted in the understanding of neurodegenerative
disorders such as AD. Battaglia et al. (2007) studied the effects
of ppTMS on LTP in a mouse model of AD and described the
mechanisms of impaired plasticity. In addition, the determined
deficits were correlated with and mirrored by TMS studies in
patients with AD. Liu et al. (2019) reported that N-methyl-D-
Glutamate (NMDAR)-related dysfunction could alter
plasticity. Coherent elaboration of the pathophysiology of AD
would facilitate the development of novel potential drugs for
modulating NMDAR function to improve plasticity, learning,
and memory in AD patients.

**Parkinson’s disease**
PD is the second most common neurologic disorder after AD
and the most complex progressive movement disorder of
aging, i.e., it mainly affects the older adult population (Váradi,
2020). Loss of dopamine in the specific area of the brain
called the substantia nigra due to abnormal protein aggregation
is the underlying mechanism of the pathogenesis of PD (Tufail,
2019). The hallmark clinical indicators are resting tremor,
rigidity, and bradykinesia.

Pooled evidence suggests that TMS may be useful as a
therapeutic intervention for PD. Pascual-Leone and colleagues
were the first to report that high-frequency rTMS (5 Hz)
facilitated contralateral hand function in normal subjects
(Pascual-Leone et al., 1994; Fregni and Pascual-Leone, 2007).
Multiple studies and meta-analyses (Fregni et al., 2005; Elahi
et al., 2009) have also confirmed the modest but significant
effects of TMS on PD motor symptoms. Although most studies have focused on the favorable effects of high-frequency stimulation (Siebner et al., 2000; Fregni and Pascual-Leone, 2007; Hamada et al., 2008; Elahi et al., 2009; Lefaucheur, 2009; Sedláčková et al., 2009), a recent study has also revealed the favorable impact of low-frequency (1 Hz) rTMS in improving motor function (Filipović et al., 2010).

Despite the enormous potential of TMS for PD therapy, the mechanisms underlying its beneficial effects are yet unexplored. Animal models are crucial to achieving an understanding of these mechanisms. It is well established that degeneration of dopaminergic neurons in the striate nucleus plays an important role in the pathogenesis of PD and replacement of these neurons alleviates PD symptoms (Zhai et al., 2019). Several animal studies have already highlighted the effects of prefrontal cortex stimulation on dopamine levels in the striate nucleus (Karreman and Moghaddam, 1996).

Kanno et al. (2003) revealed that continuous application of high-frequency (25 Hz) rTMS for 3 days in rats resulted in an improvement of motor symptoms by enhancing dopamine release in the dorsolateral striatum (Kanno et al., 2003). Keck et al. (2002) also examined the influence of high-frequency (20 Hz) rTMS on the hippocampal, striatal, and reward-related accumal dopamine levels and associated metabolites (homovanillic acid and 3,4-dihydroxyphenylacetic acid) in mouse models. The findings provided the first in vitro evidence of the positive modulatory effects of acute rTMS on both mesostriatal and mesolimbic dopaminergic neurons when employed in the frontal brain region. The increase in dopamine neurotransmission could potentially explain the preliminary findings of the beneficial effects of rTMS on PD.

Yang et al. (2010) highlighted the neuroprotective effect of rTMS on the degeneration of dopaminergic neurons in the substantia nigra of a 6-hydroxydopamine-induced rat model of PD. In addition, cyclooxygenase-2 (COX-2) and tumor necrosis factor-alpha (TNF-α) were found to be lower following rTMS in animal models. Yang et al. (2010) also observed the positive effects of decreased COX-2 and TNF-α induced by low-frequency rTMS in PD patients including increased levels of dopamine, antioxidants, and anti-inflammatory activity. These multiple animal findings have been endorsed in humans, confirming increased striatal dopamine release following rTMS to the DLPCF (Cho and Strafella, 2009).

All these related studies linked their etiological findings with mitochondrial changes through oxidative stress, as well as mitochondrial membrane potential impairment due to the pathogenesis of PD (Deas et al., 2011). The therapeutic role of TMS in improving oxidative balance and inflammation as reported by Yang et al. (2010) has also been discernibly verified by other researchers (Túnez et al., 2006; Velioglu et al., 2021).

TMS can induce neurogenesis and recovery action of lost neural populations. Following nigrostriatal denervation, 4 hours of daily stimulation for 60 days significantly increased bromodeoxyuridine-positive (Brdu+) cells localized in the subventricular zone. These newly generated proliferating neurons stained positive for tyrosine hydroxylase, i.e., they produced dopamine. In the same subjects, TMS protected against lesion-induced motor impairment (Arias-Carrion et al., 2004).

The overall findings indicate the significant importance of animal models of PD in exploring the therapeutic potential of TMS in PD patients and clarifying the mechanisms of both the remedial pathways mediated by TMS and the pathophysiology of the disease itself.

Depression
NIHBs is used to modulate brain networks and induce changes in cortical excitability by means of weak electric currents or magnetic pulses. TMS, a non-invasive brain stimulation technique, uses magnetic fields to stimulate focal cortical brain regions and neural tissues underlying the cerebral cortex (Barker et al., 1985). Due to its non-invasiveness and painlessness, TMS has become a valuable tool in neurosciences. One of the most clinically considered applications of TMS is its potential in treating the major depression. In 2008, the US Department of Health and Human Services, Food and Drug Administration (FDA) approved and permitted the marketing of TMS as a treatment for major depression. Thus, TMS is a recognized and widely accepted treatment for patients having major depressive disorder, depression-like disorders, or treatment-resistant depression (Dubin et al., 2016). The incredible potential of TMS treatment has been reported by a number of studies using animal models to examine the insight mechanism for TMS novel therapeutic approaches. However, although various researches examine the therapeutic effects of TMS on depression, the pattern of activation, the underlying mechanism behind the contribution of TMS on altering mood, and stimulation parameters (frequency, intensity, duration, and number of pulses) remain incompletely understood. rTMS exerts antidepressant effects that depend upon the frequency and intensity of stimulation applied, that is evident by animal models (Table 5). The low-frequency rTMS (1 Hz) inhibits subsequent cortical responses (Chen et al., 1997a), whereas high-frequency rTMS (15 and 10 Hz) exhibits neural facilitation (Pascual-Leone et al., 1994).

In a forced swim test (FST) model of depression, rTMS significantly decreases immobility time with a range of frequencies from 1 to 25 Hz, suggesting an anti-depressant effect. The 25-Hz frequency rTMS works more efficiently than 5- and 15-Hz frequency rTMS (Sachdev et al., 2002).

Similar to studies regarding the effects of TMS on stroke and neurodegenerative disorders, TMS treats depression through affecting neurobiological levels, molecular level, and neurogenesis. It has been observed from rat models that rTMS evokes different patterns of immediate-early gene expression that are effective for treating depression. rTMS activates the neural responses of the paraventricular nucleus of the thalamus (PVT) (Li et al., 1998). High-frequency (15 Hz) rTMS significantly increases neurogenesis, and cell proliferation in the chronic unpredictable mild stress (CUMS) exposure produces representative depression-like behavior, whereas the proliferation of hippocampus, and increases immobility time in FST. Moreover, 15-Hz rTMS reduces anhedonic-like behaviors and immobility time in FST.

Furthermore, these changes were sustained for 2 weeks after the cessation of rTMS treatment (Feng et al., 2012). Wang et al. (2014) and Zhao et al. (2018) observed comparable results. The findings suggest that rTMS administration to CUMS-exposed rat models reverses and reduces depressive-like behaviors and immobility time in FST and upregulates cell proliferation. The CB1 receptor, BDNF protein levels, and Bcl-2/Bax enhance after rTMS (Wang et al., 2014). rTMS also restores the balance of hypothalamic-pituitary-adrenocortical (HPA) axis, reduces adrenocorticotropic hormone (ACTH) and cortisol (CORT) plasma levels in a rat model of chronic unpredictable mild stress-exposed depression (Zhao et al., 2018). 10-Hz rTMS recovers cortical neural excitability, calcium-activated potassium (BK) channels, and thus reduces the depression-like behaviors in the mouse model of depression in the forced swimming test. Sun et al. (2011) reported that Homer1a gene expression was down-regulated after forced swimming but this was recovered by 10-Hz rTMS. Zuo et al. (2020) investigated the effects of 15-Hz versus 25-Hz high-frequency rTMS in a mouse model of CUMS-induced depression. HF-rTMS ameliorates depression-like and anxiety-related behaviors, as well as inhibits CUMS-induced neuronal loss and apoptosis. At both frequencies (15 Hz and 25 Hz), rTMS exerts antidepressant effects, and increase BDNF, Homer1a, p11, and p-trkB proteins level. In contrast, 15-Hz rTMS inhibits CUMS-induced neuronal loss and apoptosis,
TMS exerts therapeutic effects on depression

CUMS rat model of depression exhibits anti-depressant effects.

Gamma-aminobutyric acid (GABA) has potential anti-depressive properties, mainly by regulating apoptosis and BDNF and other protein levels. TMS was used to treat depression and similar disorders through regulating neurogenesis, synaptic plasticity, cell proliferation, and neural facilitation (Table 5). TMS remains the best choice for preclinical and clinical settings of depression treatment by electrical stimulation.

Potential Side Effects of Transcranial Magnetic Stimulation in Humans

Although TMS, first successfully demonstrated in 1985, is a non-invasive neuromodulation technique that stimulates the brain, its potential direct, long-term, or short-term side effects of magnetic stimulation must be considered. TMS is non-systemic; that is, any side effects are restricted to the brain, its potential direct, long-term, or short-term side effects of magnetic stimulation must be considered. TMS is non-systemic; that is, any side effects are restricted to the treatment area and are not spread to the other parts of the body. The current safety precautions and practice recommendations have been outlined by Wassermann (1998).

Potential Side Effects of Transcranial Magnetic Stimulation in Humans

ACTH: adrenocorticotropic hormone; BDNF: Brain-derived neurotrophic factor; CORT: corticosterone; CUMS: chronic unpredictable mild stress; FST: forced swimming test; MPFC: medial prefrontal cortex; rTMS: repetitive transcranial magnetic stimulation; TMS: transcranial magnetic stimulation.

Table 5 | TMS exerts therapeutic effects on depression

| Study | Participants/animal models | Outcome measures | TMS parameters | Effects | Results and conclusions |
|-------|-----------------------------|------------------|----------------|---------|-------------------------|
| Dubin et al., 2016 | Patients with major depressive disorder | Proton magnetic resonance spectroscopy findings | 10-Hz TMS daily for 25 d | Gamma-aminobutyric acid expression increased in MPFC relative to baseline | TMS exhibits anti-depressant effects |
| Sachdev et al., 2002 | Rat models of depression | Optimal frequency stimulation | 1, 5, 15, 25, 100 Hz rTMS, 1000 stimuli each | Decreased immobility time in FST | TMS exhibits anti-depressant effects |
| Ji et al., 1998 | CUMS rat model of depression | Immediate early gene expression | 25 Hz rTMS for 2 s 100 Hz electroconvulsive stimulation for 1 s | Induced strong neural responses in the paraventricular nucleus of the thalamus neurons in brain slices, increased c-fos expression, and regulated circadian rhythms | TMS activates brain regions |
| Feng et al., 2012 | CUMS rat model of depression | Long-term effects of chronic rTMS | 15 Hz TMS for 3 wk, also venlafaxine | Increased BDNF protein level, suppressed 5-bromo-2’-deoxyuridine-positive cell proliferation and pERK1/2 expression | Long-lasting effects and induce neuroplasticity |
| Wang et al., 2014 | Rat models of CUMS | Depression | 15 Hz TMS with 15 trains of 60 pulses | Decreased immobility time, ACTH, CORT level, and Bax, increased BCL expression, BDNF, and Bcl-2 expression in the hippocampus | TMS improves depressive behavior, neuroprotection, and treats depression |
| Zhang et al., 2018 | Rat models of CUMS | Hypothalamic-pituitary-adrenocortical axis and hippocampal neurons | 10 Hz rTMS for 15 consecutive day | Decreased ACTH, CORT, and Bax levels, restored hippocampal neurons and hypothalamic-pituitary-adrenocortical axis balance | TMS improves depressive behavior, neuroprotection, and treats depression |
| Sun et al., 2011 | Mouse model of depression | Cellular mechanism behind increase in cortical excitability in depression | 10 Hz TMS for 5 s once a day for 4 wk | Homer1a gene expression down regulated after forced swimming and recovered by TMS. Normal excitability and BK channel activity were also recovered | TMS reduces depression-like behavior and treats depression |
| Zuo et al., 2020 | Rat models of CUMS | Effects of 15 Hz versus 20 Hz TMS on depression and its molecular mechanism | 15 Hz and 20 Hz TMS for 4 wk | Upregulated p11, BDNF, Homer1a, and p-TrkB | TMS prevents neural loss, promotes neurogenesis, and exerts anti-depressant effects |
| Yang et al., 2019 | Rat models of CUMS | Effects on cognitive impairment | 1 Hz pulsed magnetic field for 2 wk | Reversed the memory, upregulated synaptic plasticity, and postsynaptic protein expression | TMS regulates synaptic function and exerts anti-depressant effects |
| Moshe et al., 2016 | Depressive rat line, rat model of hereditary drug-resistant major depressive disorder | Sub-convulsive electrical stimulation on depressive-like behaviors and BDNF level | 20 Hz sub-convulsive electrical stimulation for 10 d | Increased BDNF level | TMS reduces depressive behaviors and treats depression |

Whereas 25-Hz HF-rTMS promotes synaptic plasticity (Zuo et al., 2020). On the other hand, low-frequency pulsed magnetic fields (1 Hz) reduce depressive-like behavior and cognitive impairment in a mouse model of chronic unpredictable stress-induced depression. LF-rTMS influences the reversal memory of rats, prevents spatial learning and memory deficits (Yang et al., 2019). In another study (Moshe et al., 2016), sub-convulsive electrical stimulation, a different type of brain stimulation, was used to examine its effects on depressive-like behaviors and BDNF levels. The authors treated the prelimbic cortex of depressed rat line model with repeated sub-convulsive electrical stimulations for treatment of major depressive disorder and drug-resistant major depressive disorder. The repeated sub-convulsive electrical stimulations were found to ameliorate depressive-like behaviors and increase BDNF protein expression in the hippocampus and prefrontal cortex of a hereditary rat model of drug-resistant major depressive disorder (Moshe et al., 2016). The increase in BDNF protein expression level was also confirmed by Dubin et al. (2016). The NIBS technique, in particular TMS, has potential anti-depressive properties, mainly by regulating apoptosis and BDNF and other protein levels. TMS was used to treat depression and similar disorders through regulating neurogenesis, synaptic plasticity, cell proliferation, and neural facilitation (Table 5). TMS remains the best choice for preclinical and clinical settings of depression treatment by electrical stimulation.
Review

beyond the stimulation period itself. TMS may also generate required, unrequired, and potentially long-lasting changes to the subject area. In the context of safety, parameter combinations with short trains and long inter-train intervals carry a low risk (Rossi et al., 2009), and the intensity of TMS is a more important parameter than the frequency. Individual cortical excitability should be considered for stimulation intensity (Sack and Linden, 2003).

Discussion

TMS is a non-invasive neuromodulation procedure with relatively few adverse effects. It is most frequently used to study brain stimulation. TMS has been used extensively due to its non-invasiveness, painlessness, effectiveness, and safety. TMS significantly stimulates the brain and extensively treats stroke, ischemia, and neurodegenerative disorders. The consecutive pulses of stimulation applied with variable intervals to various brain areas or trains of repetitive stimuli at various frequencies can modulate brain activity by regulating several neurotransmitters, neurotrophic factors, cellular signaling, and cellular pathways (Tasset et al., 2012; Guo et al., 2017). TMS likely ameliorates CNS disorders by increasing BDNF, NMDA, GABA and extracellular dopamine levels, and Bcl-xL protein expression, while reducing levels of Bax and other proteins in the caspase family to inhibit apoptotic pathways. Studies have confirmed that rTMS potentially regulates neural activity, such as neurogenesis, neuronal regeneration, and neuronal excitability (Gao et al., 2010, 2017; Jin et al., 2018). However, the cellular and molecular basis of the effects exerted by TMS is still unclear.

TMS is still of great interest for research in neurological sciences because of its therapeutic effects. Animal models are very advantageous for studying the therapeutic effects of TMS and the mechanism behind its brain-stimulating activity. Thus, suitable animal models are required to assess the effects of TMS as well as its efficiency and safety. Animal models, most commonly using rats and mice, significantly contribute to studying new therapeutic interventions and TMS stimulation parameters that are yet to be investigated. Hence, animal models play a pivotal role in the study of the influence of TMS on brain activity and provide an easy way to investigate its effects at the molecular level. Various studies of neurodegenerative disorders and stroke have been performed using animal models to investigate the therapeutic effects and changes at the molecular level induced by TMS (Battaglia et al., 2007; Ba et al., 2017; Boonzaier et al., 2018).

Animal models are extensively used to investigate the therapeutic effect of TMS on neurodegenerative conditions, including AD, HD, PD, and depression. TMS could be a potential therapeutic tool to modulate neuronal function at the molecular and cellular levels, improve neuronal activity, excitability, plasticity, and functional recovery. In many neurodegenerative conditions, such as stroke, epilepsy, depression, AD, HD, and PD, a significant increase in neuronal cell death was observed due to apoptosis. Studies involving animal models have found that TMS inhibits the apoptotic pathway by decreasing apoptosis-promoting proteins (Bax, Bad, and Bcl-xS) while increasing anti-apoptotic proteins such as Bcl-2 and Bcl-xL (Fujiki et al., 2003; Yoon et al., 2011; Kale et al., 2018; Pemberton et al., 2021). TMS also reduces caspase-3 protein expression that triggers apoptosis. In addition, blocking caspase-3 expression reduces ischemic area, infarct volume, and lesion size by seizing apoptosis (Namura et al., 1998; Ferrer et al., 2003). TMS arrests the apoptosis pathway and promotes neurogenesis and neuronal regeneration, which may be the basic mechanism behind the neuroprotective effects of TMS on the brain.

TMS potentially treats different neurodegenerative disorders by stimulating various neurotransmitters and neurotrophic levels in the brain, thereby improving neuronal activity. Studies have demonstrated that TMS treatment increases BDNF expression that regulates synaptic plasticity, cortical excitability, and neurogenesis (Roslavtceva et al., 2020). BDNF promotes nerve regeneration, plasticity, and synaptic formation via tyrosine kinase receptor B (Trk-B). Following rTMS treatment, BDNF-TrkB signaling increases, which in turn stimulates BDNF-TrkB-NMDA interaction and improves cortex functioning by increasing cortical excitability (Wang et al., 2011). The rTMS treatment also ameliorates gamma-aminobutyric acid expression in neurons (Baruth et al., 2010). Additionally, TMS regulates dopamine synthesis and release. TMS promotes the survival of dopaminergic cells, thus increasing extracellular dopamine levels and significantly improving motor function (Yang et al., 2010; Ba et al., 2017). Moreover, TMS also increases intracellular Ca++ concentration and activates Ca++ channel (Tan et al., 2013a; Banerjee et al., 2017). Hence, TMS may exert neuroprotective effects by considerably regulating neurotransmitters and neurotrophic factors and promoting neurogenesis and neuromodulation.

Animal models of TMS and NIBS are the sine qua non to fully understand the impact of these techniques, optimize safety parameters, and improve clinical effectiveness. Future research should be performed to pursue results in awake animals (such as cats or nonhuman primates) and combine neuroimaging techniques (fMRI) with electrode recording to better assess these techniques for validated implementations in clinical therapy. Furthermore, a combination of TMS and neuroimaging techniques is required for the effective study of the brain and neuronal activities and to establish specific TMS treatment protocols. Specifying parameters for TMS will be necessary to optimize TMS interventions in the near future for the efficient treatment of neurological disorders.

This review has shown that:

i) Various animal models exist for the testing and development of TMS protocols.

ii) Animal models used for TMS provide insights into human diseases that TMS proposes to alleviate.

iii) Knowledge of the effects of TMS on neurotransmission and how TMS interacts with disease therapy comes from animal studies.

Conclusions

The main goal of this review was to summarize the basic understanding of TMS in brain stimulation and neurodegenerative disorders gained from animal models. In addition, we emphasized the effects of TMS and rTMS on biological parameters studied using animal models. Although there are few studies on TMS brain stimulation in animal studies, the therapeutic and neurorehabilitative effects of TMS are promising and open a pathway for researchers to further explore its molecular mechanism. rTMS has positive effects on functional recovery through neural regeneration, neurogenesis, and neuroprotection. Moreover, negative or null results should also be reported to fully understand the effectiveness of TMS. Furthermore, methodological limitations were discussed throughout this review to highlight the need for improvements in the reporting of mechanisms and practices associated with TMS.

Author contributions: All authors participated in design, writing and review of the manuscript and approved the final version of the manuscript.

Conflicts of interest: The authors declare that they have no conflicts of interest.

Financial support: None.

Copyright license agreement: The Copyright License Agreement has been signed by all authors before publication.

Plagiarism check: Checked twice by iThenticate.
Chen R, Classen J, Gerloff C, Wassermann EM, Hallett M, Cohen LG (1997a) The role of the left frontal lobe in healthy human subjects. Neurosci Lett 231:17-20.

Cappa SF, Sandrini M, Rossini PM, Sosta K, Miniussi C (2002) The role of the left frontal lobe in healthy human subjects. Neurosci Lett 231:17-20.

Brusa L, Versace V, Koch G, Bernardi G, Iani C, Stanzione P, Centonze D (2005) Improvement in cortical excitability in healthy volunteers after chronic practice of hand חברת. Neuroreport 16:3053-3057.

Boonzaier J, Petrov PI, Otte WM, Smirnov N, Neggers SFW, Dijkhuizen RM (2020) Design and implementation of a patient-specific virtual model of the human brain to study the effects of repetitive transcranial magnetic stimulation (rTMS) on cortical excitability in healthy volunteers. Front Neurol 11:568.

Bolognini N, Ro T (2010) Transcranial magnetic stimulation: disrupting neural activity to study cortical plasticity. Front Cell Neurosci 4:18.

Belov Kirdajova D, Kriska J, Tureckova J, Anderova M (2020) Ischemia-triggered glutamate excitotoxicity from the perspective of glial cells. Frontiers in cellular neuroscience. 14:51.

Belmaker RH, Grisaru N (1998) Magnetic stimulation of the brain in animal studies. J Neurosci Res 49:381-387.

Baek A, Kim JH, Pyo S, Jung JH, Park EJ, Kim SH, Cho SR (2018) The effects of transcranial magnetic stimulation on hand grip strength in healthy volunteers: a randomized controlled trial. J Neurol Neurosurg Psychiatry 89:812-816.

Arias-Carrión O, Verdugo-Díaz L, Feria-Velasco A, Millán-Aldaco D, Gutiérrez AA, Hernández-Cardona J (2020) Effects of high-field repetitive transcranial magnetic stimulation on cortical excitability in healthy volunteers. Brain Stimulation 13:175-189.

Bekier S, van der Meulen MC, Lamsma TA, Crichton J, Lammertsma AA, van Zijl PC, de Goede AA, Cullen CL, Yeo BM, van den Bergh C, van Dijk MA, van der Graaf P, Lammertsma AA (2020) Spatiotemporal dynamics of peripheral vascular endothelial growth factor changes after transcranial magnetic stimulation. Brain Stimulation 13:263-272.

Belov Kirdajova D, Kriska J, Tureckova J, Anderova M (2020) Ischemia-triggered glutamate excitotoxicity from the perspective of glial cells. Front Cell Neurosci 14:51.

Bekier S, van der Meulen MC, Lamsma TA, Crichton J, Lammertsma AA, van Zijl PC, de Goede AA, Cullen CL, Yeo BM, van den Bergh C, van Dijk MA, van der Graaf P, Lammertsma AA (2020) Spatiotemporal dynamics of peripheral vascular endothelial growth factor changes after transcranial magnetic stimulation. Brain Stimulation 13:263-272.

Belov Kirdajova D, Kriska J, Tureckova J, Anderova M (2020) Ischemia-triggered glutamate excitotoxicity from the perspective of glial cells. Front Cell Neurosci 14:51.

Bekier S, van der Meulen MC, Lamsma TA, Crichton J, Lammertsma AA, van Zijl PC, de Goede AA, Cullen CL, Yeo BM, van den Bergh C, van Dijk MA, van der Graaf P, Lammertsma AA (2020) Spatiotemporal dynamics of peripheral vascular endothelial growth factor changes after transcranial magnetic stimulation. Brain Stimulation 13:263-272.

Belov Kirdajova D, Kriska J, Tureckova J, Anderova M (2020) Ischemia-triggered glutamate excitotoxicity from the perspective of glial cells. Front Cell Neurosci 14:51.

Bekier S, van der Meulen MC, Lamsma TA, Crichton J, Lammertsma AA, van Zijl PC, de Goede AA, Cullen CL, Yeo BM, van den Bergh C, van Dijk MA, van der Graaf P, Lammertsma AA (2020) Spatiotemporal dynamics of peripheral vascular endothelial growth factor changes after transcranial magnetic stimulation. Brain Stimulation 13:263-272.

Belov Kirdajova D, Kriska J, Tureckova J, Anderova M (2020) Ischemia-triggered glutamate excitotoxicity from the perspective of glial cells. Front Cell Neurosci 14:51.

Bekier S, van der Meulen MC, Lamsma TA, Crichton J, Lammertsma AA, van Zijl PC, de Goede AA, Cullen CL, Yeo BM, van den Bergh C, van Dijk MA, van der Graaf P, Lammertsma AA (2020) Spatiotemporal dynamics of peripheral vascular endothelial growth factor changes after transcranial magnetic stimulation. Brain Stimulation 13:263-272.

Belov Kirdajova D, Kriska J, Tureckova J, Anderova M (2020) Ischemia-triggered glutamate excitotoxicity from the perspective of glial cells. Front Cell Neurosci 14:51.

Bekier S, van der Meulen MC, Lamsma TA, Crichton J, Lammertsma AA, van Zijl PC, de Goede AA, Cullen CL, Yeo BM, van den Bergh C, van Dijk MA, van der Graaf P, Lammertsma AA (2020) Spatiotemporal dynamics of peripheral vascular endothelial growth factor changes after transcranial magnetic stimulation. Brain Stimulation 13:263-272.

Belov Kirdajova D, Kriska J, Tureckova J, Anderova M (2020) Ischemia-triggered glutamate excitotoxicity from the perspective of glial cells. Front Cell Neurosci 14:51.

Bekier S, van der Meulen MC, Lamsma TA, Crichton J, Lammertsma AA, van Zijl PC, de Goede AA, Cullen CL, Yeo BM, van den Bergh C, van Dijk MA, van der Graaf P, Lammertsma AA (2020) Spatiotemporal dynamics of peripheral vascular endothelial growth factor changes after transcranial magnetic stimulation. Brain Stimulation 13:263-272.

Belov Kirdajova D, Kriska J, Tureckova J, Anderova M (2020) Ischemia-triggered glutamate excitotoxicity from the perspective of glial cells. Front Cell Neurosci 14:51.

Bekier S, van der Meulen MC, Lamsma TA, Crichton J, Lammertsma AA, van Zijl PC, de Goede AA, Cullen CL, Yeo BM, van den Bergh C, van Dijk MA, van der Graaf P, Lammertsma AA (2020) Spatiotemporal dynamics of peripheral vascular endothelial growth factor changes after transcranial magnetic stimulation. Brain Stimulation 13:263-272.
Guo F, Lou J, Lian X, Deng Y, Huang X (2017) Repetitive transcranial magnetic stimulation ameliorates cognitive impairment by enhancing neurogenesis and suppressing apoptosis in the hippocampus in rats with ischemic stroke. Front Pharmacol 8:559.

Guo F, Han X, Zhang X, Huang X, Liu C, Lou J, Huang X (2014) Repetitive transcranial magnetic stimulation promotes neural stem cell proliferation via upregulating MiR-25 in a rat model of focal cerebral ischemia. PloS One 9:e90267.

Hamada K, Kuwabara S (2003) The influence of the electric field on the development of the brain. National Institute for Physiological Sciences Disease Study Group, Japan (2008) High-frequency rTMS over the supplementary motor area for treatment of Parkinson’s disease. Mov Disord 23:1524-1531.

Hanlon CA, Dowdle GE (2016) Modulating neural circuits with transcranial magnetic stimulation: implications for addiction treatment development. Pharmacol Rev 70:661-683.

Hartmann CJ, Groiss SJ, Vesper J, Schnitzler A, Wojtzek L (2016) Brain stimulation in Huntington’s disease. Neurodegener Dis Manag 6:223-236.

Hickman S, Izsy S, Sen P, Morst L, El Khoury J (2018) Microglia in neurodegeneration. Nat Rev Neurosci 19:11-29.

Hong Y, Liu Q, Peng M, Bai M, Li S, Sun G, Guo H, Xu P, Xie Y, Li Y, Liu D, Li J, Xie Y, Bu W, Xu G (2020) High-frequency repetitive transcranial magnetic stimulation improves functional connectivity of the default mode network by modulating neurotoxic polarization of astrocytes in rats. J Neuroinflammation 17:150.

Houlton J, Alburquerque N, Hinkley SFR, Gonzalez AN (2019) Therapeutic potential of rTMS in Parkinson’s disease: the value of transcranial magnetic stimulation. Curr Med Chem 27:2482-2491.

Merton PA, Morton HB (1980) Stimulation of the cerebral cortex in the intact human subject. Nature 285:227-242.

Namura S, Zhu J, Fink K, Endres M, Srinivasan A, Tomaselli KJ, Huang XL, Moskowitz MA (1998) Activation and cavage of caspase-3 in apoptosis induced by experimental cerebral ischemia. J Neurosci 18:3659-3668.

Namur S, Gregoire L, Martin A, Lebon (2020) Influence of voluntary contraction level, test stimulus intensity and normalisation procedures on the evaluation of short-interval intracortical inhibition. Brain Sci 10:413.

Nikkilä R, Kroiv MG, Agostini M, Amelio I, Melino G (2020) Regulation of adult neurogenesis in mammalian brain. J Mol Cell Sci 21:4869-4879.

Obreza PA (1973) Magnetic stimulation of nerve tissue. Med Biol Eng 11:55-64.

Odean M (2019) Astrocyte plasticity: a possible role of astrocytes in neuroprotection may influence neuronal Bcl-2 and Fas protein expression in the CA1 region of the hippocampus. Neurogen Regen Res 5:895-900.

Keck ME, Wirtz T, Müller MB, Erhardt A, Ohi F, Toschi N, Holboer S, Silbaver I (2002) Repetitive transcranial magnetic stimulation increases the release of dopamine in the limbic striatum: an effect mediated by ventral tegmental area. Neurochem Int 36:59-98.

Ko JH, Monchi O, Ptito A, Bloomfield P, Houle S, Strafella AP (2008) Theta burst stimulation--Clinical applications. J Clin Neurophysiol 25:467-475.

Kremer KL, Smith AE, Sandeman L, Inglis JM, Ridding MC, Koblar SA (2016) Transcranial magnetic stimulation modifies microglial morphology in mice. Eur Neurol 76:131-141.

Kremer KL, Smith AE, Sandeman L, Inglis JM, Ridding MC, Koblar SA (2016) Transcranial magnetic stimulation in permanent stroke rat model. J Exp Stroke Transl Neurosci 12:1613-1619.

Krol KL, Smith AE, Sandeman L, Inglis JM, Ridding MC, Koblar SA (2016) Transcranial magnetic stimulation modifies microglial morphology in mice. Eur Neurol 76:131-141.

Luo J, Zheng H, Zhang L, Zhang Q, Li P, Lei Z, Hu X (2017) High-frequency repetitive transcranial magnetic stimulation (rTMS) facilitates functional recovery by enhancing neurogenesis and activating BDNF/TMBG signaling in rats. Int J Mol Sci 18:4555.

Luo Y, Yuan Y, Wang H, Gan Z, Rane G, Cao X, Guo Z, Liu J, Cui X (2014) Repetitive transcranial magnetic stimulation promotes neural stem cell proliferation via upregulating MiR-10b in vitro. J Huazhong Univ Sci Technolog (Med Sci) 35:666-772.

Lu J, Chang L, Song Y, Li H, Wu Y (2019) The role of NMDA receptors in Alzheimer’s disease. Front Neurol 10:133.

Luo X, Zopp M (2016) Astrocytes, therapeutic targets for neuroprotection and neuroregeneration. Prog Neurobiol 144:131-162.

Lorenzo C, Dinapoli L, Gillo S, Suppa A, Bagnato S, Curra A, Inghilleri M, Berardelli A (2006) Motor cortical excitability studied with repetitive transcranial magnetic stimulation in patients with Huntington’s disease. Clin Neurophysiol 117:1677-1681.
Schwarz S, Hracke W, Schweb S (2000) Magnetic evoked potentials in neurocritical care patients with acute brainstem lesions. J Neurol Sci 172:30-37.

Sedáčková S, Řehůřeková I, Svoňová H, Riečan B (2009) Effect of high frequency repetitive transcranial magnetic stimulation on reaction time, clinical features and cognitive functions in patients with Parkinson’s disease. J Neurol Transm (Vienna) 116:1093-1101.

Seifert G, Steinhauser C (2013) Neuron astrocite signaling and epilepsy. Exp Neurol 244:4-10.

Siebler NR, Rossmeier C, Mentschel C, Peinemann A, Conrad B (2000) Short-term motor improvement after sub-threshold 5-Hz repetitive transcranial magnetic stimulation of the primary motor hand area in Parkinson’s disease. J Neurol Sci 178:91-94.

Singh A, Erwin-Grabner T, Goya-Maldonado R, Antal A (2020) Transcranial magnetic and direct current current in the treatment of depression: basic mechanisms and challenges of two commonly used brain stimulation methods in interventional psychiatry. Neuropsychobiology 79:397-407.

Stateman WA, Knöppel A, Poclicksio SJ, Henkin RI (2014) Repetitive transcranial magnetic stimulation (rTms) increases plasma calcium both in vivo and in vitro. J Clin Exp Pathol 4:187.

Sun P, Wang F, Wang L, Zhang Y, Yamamoto R, Sugai F, Zhang Q, Wang Z, Kato N (2011) Increase in cortical pyramidal cell excitability accompanies depression-like behavior in mice: a transcranial magnetic stimulation study. J Neurosci 31:16464-16472.

Sun Y, Jin K, Childs JT, Lai M, Xiao Q, Greenberg DA (2006) Vascular endothelial growth factor-B (VEGFB) stimulates neurogenesis: evidence from knockout mice and growth factor administration. Dev Biol 289:329-335.

Szebeni A, Szebeni K, DiPeri T, Chandley MJ, Crawford JD, Stockmeier CA, Ordway GA (2014) Shortened telomere length in white matter oligodendrocytes in major depression: potential role of oxidative stress. Int J Neuropsychopharmacol 17:1579-1589.

Tan T, Xie J, Tong Z, Li X, Chen X, Tian X (2013a) Repetitive transcranial magnetic stimulation increases excitability of hippocampal CA1 pyramidal neurons. Brain Res 1520:23-35.

Tan T, Xie J, Li X, Chen X, Zheng X, Tong Z, Tian X (2013b) Low-frequency (1 Hz) repetitive transcranial magnetic stimulation (rTMS) reverses Aβ(1-42) mediated memory deficits in rats. Exp Gerontol 48:786-794.

Tábara I, Medina FJ, Jimena I, Aguera E, Gascon S, Feijóo M, Sánchez-López F, Luque E, Peña J, Drucker-Colin R, Tüenzé I (2012) Neuroprotective effects of low-frequency electromagnetic fields on a Huntington’s disease rat model: effects on neurotrophic factors and neuronal density. Neuroscience 209:54-63.

Trippé J, Mx A, Aydin-Abidin S, Funke K, Bernali A (2009) B burn and conventional low-frequency rTMS differentially affect GABAergic neurotransmission in the rat cortex. Exp Brain Res 199(3-4):411-421.

Tufail M (2019) Clinical features and risk factors of Parkinson’s disease in a population of Khyber Pakhtunkhwa, Pakistan: a case-control study. Neurodegerener Dis 19(5-6):211-217.

Tüenzé I, Drucker-Colin R, Jimena I, Medina FJ, Muñoz Mdel C, Peña J, Montilla P (2006) Transcranial magnetic stimulation attenuates cell loss and oxidative damage in the striatum induced in the 3-nitropropionic model of Huntington’s disease. J Neurochem 97:619-630.

Valério-Gomes B, Guimarães DM, Szcupac D, Lent R (2018) The absolute number of oligodendrocytes in the adult mouse brain. Front Neurosci 12:10.

Várádi C (2020) Clinical features of parkinson’s disease: the evolution of critical symptoms. J Neurol Sci 18:125-127.

Velegolu HA, Haroqui L, Bayraktaroglu Z, Toprak G, Guler EM, Bektay MY, Mutlu-Burnaz O, Yulug B (2021) Left lateral parietal rTMS improves cognition and modulates resting brain connectivity in patients with Alzheimer’s disease: Possible role of BDNF and oxidative stress. Neurobiol Learn Mem 180:107419.

Volkow ND, Michaelides M, Balcer R (2019) The neuroscience of drug reward and addiction. Physiol Rev 99:2115-2140.

Wagner T, Valero-Cabre A, Pascual-Leone A (2007a) Noninvasive human brain stimulation. Annu Rev Biomed Eng 9:527-565.

Wagner T, Fregni F, Fecteau S, Grodzinsky A, Zahn M, Pascual-Leone A (2007b) Transcranial direct current stimulation: a computer-based human model study. Neuroimage 35:1113-1124.

Wang WN, Wang L, Zhang RG, Chen YC, Liu L, Gao F, Nie H, Hou W, Peng ZW, Tan Q (2014) Anti-depressive mechanism of repetitive transcranial magnetic stimulation in rat: the role of the endocannabinoid system. J Psychiatr Res 51:79-87.

Wang HY, Crups O, Liu J, Stucky A, Crucita G, Di Rocco A, Friedman E, Quattroone A, Ghilardi MF (2011) Repetitive transcranial magnetic stimulation enhances BDNF-TrkB signaling in both brain and lymphocyte. J Neurosci 31:11044-11054.

Wassermann EM (1998) Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5–7, 1996. Electrocephaologr Clin Neurophysiol 108:1-16.

Weissman JD, Epstein CM, Davey KR (1992) Magnetic brain stimulation and brain size: relevance to animal studies. Electrocephaologr Clin Neurophysiol 85:215-219.

Wu C, Sun D (2015) GABA receptors in brain development, function, and injury. Metab Brain Dis 30:367-379.

Yang J, Wang L, Wang F, Tang X, Zhou P, Liang R, Zheng C, Ming D (2019) Low-frequency pulsed magnetic field improves depression-like behaviors and cognitive impairments in depressive rats mainly via modulating synaptic function. Front Neurosci 13:820.

Yang L, Wang SH, Hu Y, Sui YF, Peng T, Guo TC (2018) Effects of repetitive transcranial magnetic stimulation on astrocytes proliferation and nNOS expression in neuropathic pain rats. Curr Med Sci 38:482-490.

Yang L, Su Y, Guo F, Zhang H, Zhao Y, Huang Q, Xu H (2020) Deep rTMS mitigates behavioral and neuropathologic abnormalities in cuprizone-exposed mice through reducing microglial proinflammatory cytokines. Front Integr Neurosci 14:556839.

Yang X, Song L, Liu Z (2010) The effect of repetitive transcranial magnetic stimulation on a model rat of Parkinson’s disease. Neuroreport 21:268-272.

Yoon KJ, Lee YT, Han TR (2013) Mechanism of functional recovery after repetitive transcranial magnetic stimulation (rTMS) in the subacute cerebral ischemic rat model: neural plasticity or anti-apoptosis? Exp Brain Res 214:549-556.

Zhai S, Shen W, Graves SM, Surmeier DJ (2019) Dopaminergic modulation of striatal function and Parkinson’s disease. J Neurol Transm (Vienna) 126:411-422.

Zhang N, Xing M, Wang Y, Tao H, Cheng Y (2015) Repetitive transcranial magnetic stimulation enhances spatial learning and synaptic plasticity via the VEGF and BDNF-NMDAR pathways in a rat model of vascular dementia. Neuroscience 311:284-291.

Zhang XQ, Li L, Huo JT, Cheng M, Li LH (2018) Effects of repetitive transcranial magnetic stimulation on cognitive function and cholinergic activity in the rat hippocampus after vascular dementia. Neuro Regen Res 13:1384-1389.

Zhao L, Ren H, Gu S, Li X, Jiang C, Li J, Zhang M, Mu J, Li W, Wang W, Zhang Z, Song J (2018) rTMS ameliorated depressive-like behaviors by restoring HPA axis balance and prohibiting hippocampal neuron apoptosis in a rat model of depression. Psychiatry Res 269:126-133.

Zhao SC, Ma LS, Chu ZH, Xu H, Wu WQ, Liu F (2017) Regulation of microglial activation in stroke. Acta Pharmacol Sin 38:445-458.

Zhao X, Moore DL (2018) Neural stem cells: developmental mechanisms and disease modeling. Cell Tissue Res 371:1-6.

Zorzo C, Higasa SG, Méndez M, Martinez JA, Pernia AM, Arias JL (2019) High frequency repetitive transcranial magnetic stimulation improves neuronal activity without affecting astrocytes and microglia density. Brain Res Bull 150:13-20.

Zuo C, Cao Y, Ding F, Zhao J, Huang Y, Li G, Huang S, Jiang H, Jiang Y, Wang F (2020) Neuroprotective efficacy of different levels of high frequency repetitive transcranial magnetic stimulation in mice with CUMS-induced depression: Involvement of the p11/ BDNF/Homer1a signaling pathway. J Psychiatr Res 125:152-163.